![](/images/graphics-bg.png)
Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy
Joint Authors
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-03-22
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Warm autoimmune hemolytic anemia (wAIHA) is the most common form of AIHA, with corticosteroids in first-line treatment resulting in a 60–80% response rate.
Atypical wAIHA and IgG plus complement mediated disease have a higher treatment failure rate and higher recurrence rate.
We report a case of severe wAIHA secondary to Waldenström macroglobulinemia with life threatening intravascular hemolysis refractory to prednisone, rituximab, splenectomy, and plasmapheresis.
A four-week treatment of eculizumab in this heavily pretreated patient resulted in a sustained increase in hemoglobin and transfusion independence, suggesting a role for complement inhibition in refractory wAIHA.
American Psychological Association (APA)
Ma, Kim& Caplan, Stephen. 2016. Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy. Case Reports in Hematology،Vol. 2016, no. 2016, pp.1-3.
https://search.emarefa.net/detail/BIM-1100895
Modern Language Association (MLA)
Ma, Kim& Caplan, Stephen. Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy. Case Reports in Hematology No. 2016 (2016), pp.1-3.
https://search.emarefa.net/detail/BIM-1100895
American Medical Association (AMA)
Ma, Kim& Caplan, Stephen. Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy. Case Reports in Hematology. 2016. Vol. 2016, no. 2016, pp.1-3.
https://search.emarefa.net/detail/BIM-1100895
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1100895